Safety of Long-Term Administration of Bisphosphonates in Elderly Cancer Patients

Oncology ◽  
2004 ◽  
Vol 67 (2) ◽  
pp. 112-116 ◽  
Author(s):  
Paolo Tralongo ◽  
Lazzaro Repetto ◽  
Anna Di Mari ◽  
Gaetano Mauceri ◽  
Roberto Bollina ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Elderly Cancer Patients ◽  
Term Administration

scholarly journals INFLUENCE OF LONG-TERM CYTOTOXIC CHEMOTHERAPY ON THE CONDITION OF PERIPHERAL VENOUS CHANNEL

2017 ◽  
Vol 3 ◽  
pp. 49-55
Author(s):  
Tetiana Tkachuk
Keyword(s):  
Cancer Patients ◽  
Vascular Access ◽  
Venous Access ◽  
Term Treatment ◽  
Cytotoxic Chemotherapy ◽  
Cytotoxic Therapy ◽  
Qualitative And Quantitative ◽  
Long Term Treatment ◽  
Term Administration

The necessity of long-term venous access in cancer patients appears at frequent and long-term courses of cytotoxic therapy. Peripheral veins of forearms are most often used for these aims. The conditions of peripheral venous channel in 32 cancer patients, who underwent the long-term treatment with antitumor preparations were analyzed in the article on own investigatory material. The methods of dopplerography, morphological and immunohystochemical studies were used. The qualitative and quantitative dopplerographic changes in forearm veins in different terms after chemotherapy start were revealed in most patients. The conclusion was made about unsuitability of forearm peripheral veins for the long term administration of cytostatics and the necessity to create the alternative vascular access that would correspond to the criteria of safety, reliability and long-term exploitation.

scholarly journals Long Term Outcomes of a Geriatric Liaison Intervention in Frail Elderly Cancer Patients

PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0143364 ◽  
Author(s):  
Liesbeth Hempenius ◽  
Joris P. J. Slaets ◽  
Dieneke van Asselt ◽  
Truuske H. de Bock ◽  
Theo Wiggers ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Frail Elderly ◽  
Long Term Outcomes ◽  
Elderly Cancer Patients

scholarly journals TESTICULAR ENDOCRINE FUNCTION IN PROSTATIC CANCER PATIENTS RECEIVING MEDICAL CASTRATION BY LONG-TERM ADMINISTRATION OF LH-RH AGONISTS

1989 ◽  
Vol 80 (10) ◽  
pp. 1466-1473
Author(s):  
Koichiro Isurugi ◽  
Yasushi Kondo ◽  
Kiyoshi Hirasawa ◽  
Tsuneo Oyamatsu ◽  
Yukio Honma
Keyword(s):  
Cancer Patients ◽  
Prostatic Cancer ◽  
Endocrine Function ◽  
Term Administration ◽  
Lh Rh

scholarly journals Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration

1999 ◽  
Vol 10 (6) ◽  
pp. 701-706 ◽  
Author(s):  
E. Briasoulis ◽  
V. Karavasilis ◽  
D. Anastasopoulos ◽  
E. Tzamakou ◽  
G. Fountzilas ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Dose Escalation ◽  
Dose Escalation Study ◽  
Weekly Docetaxel ◽  
Cumulative Toxicity ◽  
Term Administration

How I treat venous thromboembolism in patients with cancer

Blood ◽  
2005 ◽  
Vol 106 (13) ◽  
pp. 4027-4033 ◽  
Author(s):  
Paolo Prandoni
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Outpatient Setting ◽  
Bleeding Complications ◽  
Fixed Dose ◽  
Patients With Cancer ◽  
Term Administration ◽  
Adjusted Dose

Venous thromboembolism (VTE) is a frequent complication in cancer patients and represents an important cause of morbidity and mortality. Especially in patients who have a poor life expectancy, preventing death from pulmonary embolism is the mainstay of treatment. Critically ill patients should promptly be administered thrombolytic drugs. Except for selected patients requiring aggressive therapy, the initial VTE treatment should be conducted with either adjusted-dose unfractionated heparin or fixed-dose low-molecular-weight heparin (LMWH). LMWHs have the potential to greatly simplify the initial treatment of VTE, making the treatment of suitable patients feasible in an outpatient setting. During anticoagulant therapy, cancer patients have a 2- to 4-fold higher risk of recurrent VTE and major bleeding complications when compared with noncancer patients. The long-term administration of LMWH should be considered as an alternative to anti-vitamin K drugs in patients with advanced disease and in those with conditions limiting the use of oral anticoagulants. Prolongation of anticoagulation should be considered for as long as the malignant disorder is active. The evidence of lowered cancer mortality in patients on LMWH has stimulated renewed interest in these agents as antineoplastic drugs and raises the distinct possibility that cancer and thrombosis share common mechanisms.

Sign in / Sign up

Export Citation Format

Share Document